AB1010 WHICH FACTORS ARE ASSOCIATED WITH CLINICALLY HIGH DISEASE ACTIVITY IN AXIAL SPONDYLOARTHRITIS? RESULTS FROM THE INTERNATIONAL MAP OF AXIAL SPONDYLOARTHRITIS (IMAS)

Background Active axial spondyloarthritis (axSpA) is associated with poorer physical and mental health outcomes. Objectives This study aims to assess the prevalence of clinically active disease in axSpA its factors a large sample patients from International Map Axial Spondyloarthritis (IMAS) around globe. Methods IMAS cross-sectional online survey (2017-2022) including 5,557 unselected patients. Patients were divided between those (BASDAI < 4) without ≥ 4). The evaluated were: age, gender, activity engagement, work-related issues, work choice difficulty finding job due axSpA, number self-reported symptomatic body regions, diagnostic delay, HLA-B27, extra-musculoskeletal manifestations, spinal stiffness (3-12), functional limitation (0-54), using GHQ-12 scale (0-12), treatments (NSAIDs, csDMARDs bDMARDs). Mann-Whitney, chi-square test logistic regression analysis used evaluate possible association investigated Results 5,295 who had responded BASDAI included present study: 3,231 Europe, 770 North America, 600 Asia, 548 Latin 146 Africa. mean age was 43.8±12.9 years 55.4% females. Patient reported 5.4 ( Figure 1 ) 75% having (BASDAI≥4). In South Africa, 87.0% disease, compared 68.5% Asia. Compared non-active more likely be older, female, physically inactive, experience have greater faced limited higher longer proportion HLA-B27 negative, presence inflammatory bowel stiffness, limitation, worse health, use csDMARDs. multivariable regression, issues Table ). Conclusion Globally, three four Africa lower causal relationship identified clinical complex may vary patient patient. Our results underline complexity concept need holistic approach management. 1. Mean median by region (N= 5,295) Logistic determine 2,630) Univariable Multivariable OR CI 95% Age 0.99 0.98, 1.01 Gender. Female 1.95 1.72, 2.21 1.14 0.84, 1.56 Physical engagement. No 1.34 1.12, 1.59 1.19 0.77, 1.85 No. regions 1.12 1.11, 1.08 1.04, 1.11 Spinal Stiffness (3-12) 1.39 1.35, 1.43 1.37 1.27, 1.47 Functional Limitation (0-54) 1.05 1.02 1.01, 1.03 Diagnostic Delay 0.98 0.96, HLA-B27. Negative 1.22 1.76 1.48 1.06, 2.08 Inflammatory disease. Yes 1.82 1.48, 2.23 0.90, 2.28 Difficulty axSpA. 5.08 4.38, 5.90 1.92 1.38, 2.68 Work-related 3.16 2.70, 3.69 1.73 1.22, 2.44 Work 2.10 1.84, 2.41 0.75, 1.41 Mental (0-12) 1.27 1.24, 1.29 1.20 1.14, 1.26 Use 1.18 1.03, 1.35 0.82, 1.49 Acknowledgements supported Novartis Pharma AG. authors would like thank all participated study. Disclosure Interests Marco Garrido-Cumbrera Grant/research support from: Novartis, Victoria Navarro-Compán Speakers bureau: AbbVie, Eli Lilly, Janssen, MSD, Pfizer, UCB Pharma, Consultant of: Galapagos, MoonLake, Fernando Sommerfleck Abbvie, Christine Bundy Celgene, Souzi Makri GSK Bayer, José Correa-Fernández: None declared, SHASHANK MURLIDHAR AKERKAR Jansen, Jo Davies personal funding, but ASIF has received funding UCB, Boehringer Ingleheim, Elie Karam: Asif Siddiqui Employee employment stock ownership, Denis Poddubnyy BMS, Roche Pfizer.